尖峰集团：恩格列净获得化学原料药上市申请批准通知书

Core Viewpoint - Jianfeng Group's subsidiary, Zhejiang Jianfeng Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the marketing application of the chemical raw material drug, Empagliflozin, which is an SGLT2 inhibitor used as an adjunct treatment for blood sugar control in adult patients with type II diabetes [1] Group 1 - Empagliflozin functions by blocking the reabsorption of glucose in the kidneys, leading to the excretion of excess glucose and thereby lowering blood sugar levels [1] - The glucose-lowering effect of Empagliflozin does not depend on β-cell function and insulin resistance [1] - As of the announcement date, there are 28 companies listed on the CDE raw and auxiliary materials registration information platform with status "A," including Jiangsu Hengrui Medicine Co., Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. [1]